Ensign Peak Advisors’s Krystal Biotech KRYS Stock Holding History

Ensign Peak Advisors’s Portfolio KRYS Stock Details KRYS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$509K	Hold	1,369	–	–	﹤0.01%	978
2026 Q1	$354K	Hold	1,369	–	–	﹤0.01%	1067
2025 Q4	$338K	Sell	1,369 -3,050	-69%	-$642K	﹤0.01%	1073
2025 Q3	$780K	Sell	4,419 -2,150	-33%	-$322K	﹤0.01%	1158
2025 Q2	$903K	Hold	6,569	–	–	﹤0.01%	1297
2025 Q1	$1.18M	Hold	6,569	–	–	﹤0.01%	1158
2024 Q4	$1.03M	Hold	6,569	–	–	﹤0.01%	1303
2024 Q3	$1.2M	Hold	6,569	–	–	﹤0.01%	1224
2024 Q2	$1.21M	Sell	6,569 -14,348	-69%	-$2.41M	﹤0.01%	1162
2024 Q1	$3.72M	Buy	20,917 +14,017	+203%	+$1.95M	0.01%	718
2023 Q4	$856K	Hold	6,900	–	–	﹤0.01%	1466
2023 Q3	$800K	Buy	6,900 +2,050	+42%	+$250K	﹤0.01%	1362
2023 Q2	$569K	Buy	+4,850	New	+$495K	﹤0.01%	1599
2022 Q4	–	Sell	-3,670	Closed	-$256K	–	2013
2022 Q3	$256K	Buy	+3,670	New	+$265K	﹤0.01%	1775
2021 Q4	–	Sell	-34,596	Closed	-$1.81M	–	2217
2021 Q3	$1.81M	Buy	+34,596	New	+$2.05M	﹤0.01%	1185

Other funds holding KRYS

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Ensign Peak Advisors's KRYS Position: Q2 2026 in Review

Ensign Peak Advisors held its Krystal Biotech (KRYS) position steady in Q2 2026 at 1,369 shares worth $509K. The position accounts for ﹤0.01% of the portfolio, ranked #978.

Ensign Peak Advisors first reported a position in KRYS in Q3 2021 and has held it in 15 quarters since. The position peaked at $3.72M in Q1 2024. 424 funds tracked by Wall St. Rank hold KRYS as of Q2 2026.

Ensign Peak Advisors held 1,369 shares of Krystal Biotech worth $509K as of Q2 2026.
Ensign Peak Advisors left its Krystal Biotech share count unchanged in Q2 2026.
Krystal Biotech made up ﹤0.01% of Ensign Peak Advisors's portfolio in Q2 2026, its #978 holding.
Ensign Peak Advisors first reported a position in Krystal Biotech in Q3 2021 and has held it in 15 quarters since.
Ensign Peak Advisors's Krystal Biotech position peaked at $3.72M in Q1 2024.
424 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2026.

Based on Ensign Peak Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.